In breast and ovarian cancer tumors with a known mutation in HR genes, such as BRCA1 or BRCA2, a higher tumor mutational burden and a greater number of tumor-infiltrating lymphocytes have been observed [33]; however, this outcome did not occur in our cohort. The gene discussed is BRCA1; the disease is ovarian cancer.